According to GlobalData’s medical device pipeline database, 24 Other Colorectal Cancer Screening Tests devices are in various stages of development globally. GlobalData’s report Other Colorectal Cancer Screening Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 19 are in active development, while the remaining five are in an inactive stage of development. There are three products in the early stages of development, and the remaining 16 are in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. Other Colorectal Cancer Screening Tests refer to diagnostic tests to detect the presence of colorectal cancer. Tests which don’t fall under Guaiac Fecal Occult Blood Test (gFOBT) Kits, Immunochemical Fecal Occult Blood Test (iFOBT or FIT) Kits, Fecal DNA Test Kits are tracked here. Other colorectal cancer screening tests covered in this market include blood-based assays that are used to screen for colorectal cancer by identifying changes in the methylation status of the Septin 9 gene.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Other Colorectal Cancer Screening Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Other Colorectal Cancer Screening Tests devices. Overall, most of these Other Colorectal Cancer Screening Tests pipeline devices are being developed by private entities.
Key players involved in the active development of Other Colorectal Cancer Screening Tests include Guardant Health, iCellate Medical, Interpace Biosciences, mBioSys, Oncodiag, QuantuMDx Group, Rarity Bioscience, Shanghai Singlera Genomics Technologies, Singlera Genomics and University of Oxford.
For a complete picture of the developmental pipeline for Other Colorectal Cancer Screening Tests devices, buy the report here.